At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Felzartamab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy
In Brief
A Phase 2 clinical trial evaluating Felzartamab and Placebo for Immunoglobulin A (IgA) Nephropathy. Completed, enrolled 54 participants across 59 sites in 15 countries.
Detailed Summary
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunoglobulin A (IgA) Nephropathy
CountriesAustralia, Belgium, Bulgaria, Czechia, Georgia, Germany, Japan, Malaysia, Philippines, Serbia, South Korea, Spain, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartAug 2021
First PostedOct 2021
Primary CompletionFeb 2023
Study CompletionMay 2024
TodayJul 2026
First PostedOct 4, 2021
Enrollment StartAug 31, 2021
Primary CompletionFeb 6, 2023
Study CompletionMay 6, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.7 years ago
Interventions
Felzartamabdrug
anti-CD38+ monoclonal antibody
Placeboother
Placebo comparator